(+)-Magnoflorine

Synonyms: Magnoflorine; α-Magnoflorine; Thalictrine
(+)-Magnoflorine (α-Magnoflorine) 是一种口服有效的、具有多种生物活性的阿朴啡类生物碱,它通过促进 Parkin/PINK1 介导的线粒体自噬 (autophagy)、抑制 NLRP3/Caspase-1 通路的激活并调节肠道菌群而具有显著的抗炎与免疫调节活性,通过抑制 JNK 和 TLR4/NF-κB 信号通路并激活 Sirt1/AMPK 通路而减轻神经元氧化应激和凋亡 (apoptosis),通过上调 miR-410-3p 并抑制 HMGB1/NF-κB 通路而具有抗肿瘤活性,同时还具有显著的抗真菌活性。
产品编号: MS-Z44211 CAS No.: 2141-09-5 分子式: C20H24NO4+ 分子量: 342.41
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

(+)-Magnoflorine (α-Magnoflorine) 是一种口服有效的、具有多种生物活性的阿朴啡类生物碱,它通过促进 Parkin/PINK1 介导的线粒体自噬 (autophagy)、抑制 NLRP3/Caspase-1 通路的激活并调节肠道菌群而具有显著的抗炎与免疫调节活性,通过抑制 JNK 和 TLR4/NF-κB 信号通路并激活 Sirt1/AMPK 通路而减轻神经元氧化应激和凋亡 (apoptosis),通过上调 miR-410-3p 并抑制 HMGB1/NF-κB 通路而具有抗肿瘤活性,同时还具有显著的抗真菌活性。

生物实验数据

生物活性 (+)-Magnoflorine (α-Magnoflorine) is an orally effective aporphine alkaloid with diverse biological activities that exhibits significant anti-inflammatory and immunomodulatory activity by promoting Parkin/PINK1-mediated mitophagy (autophagy), inhibiting activation of the NLRP3/Caspase-1 pathway, and modulating the gut microbiota; attenuates neuronal oxidative stress and apoptosis (apoptosis) by inhibiting the JNK and TLR4/NF-κB signaling pathways and activating the Sirt1/AMPK pathway; exerts antitumor activity by upregulating miR-410-3p and inhibiting the HMGB1/NF-κB pathway; and also possesses significant antifungal activity.
体外研究
(In Vitro)

(+)-Magnoflorine 对 Penicillium avellaneum UC-4376、T. rubrum 和 T. mentagrophyte 表现出强大的抗真菌活性,MIC 分别为 5 μg/disc、62.5 μg/mL 和 62.5 μg/mL。
(+)-Magnoflorine (5-80 μM,24 h) 可抑制 MG-63 和 U-2 OS 细胞的增殖、侵袭和上皮-间质转化过程。
(+)-Magnoflorine (10-40 μM,24 h) 可上调 miR-410-3p,从而抑制 HMGB1/NF-κB 通路。
(+)-Magnoflorine (10 μM,27 h) 可显著逆转 Aβ1-42 引起的 PC12 细胞活力下降,并降低细胞凋亡率。
(+)-Magnoflorine (10 μM,27 h) 显著降低 Aβ1-42 引起的细胞内 ROS 水平升高,并恢复受损的线粒体膜电位。
(+)-Magnoflorine (0-50 μM,24 h) 通过促进 Parkin 依赖性线粒体自噬抑制 HK-2 细胞中 NLRP3 炎症小体的激活。

Cell Invasion Assay

Cell Line: MG-63 and U-2 OS cells
Concentration: 10, 20 and 40 μM
Incubation Time: 24 h
Result: Significantly reduced the number of MG-63 and U-2 OS cells passing through the matrix gel.

RT-PCR

Cell Line: MG-63 and U-2 OS cells
Concentration: 10, 20 and 40 μM
Incubation Time: 24 h
Result: Upregulated the mRNA expression of E-cadherin in a dose-dependent manner, and downregulate the expressions of N-cadherin and Vimentin.
Dose-dependently down-regulates the mRNA expression of HMGB1.
Inhibited the activation of the NF-κB pathway resulting in a decrease in the levels of phosphorylated-p65 and phosphorylated-IκBα.
Significantly upregulated the expression of miR-410-3p in osteosarcoma cells.

Western Blot Analysis

Cell Line: MG-63 and U-2 OS cells
Concentration: 10, 20 and 40 μM
Incubation Time: 24 h
Result: Upregulated the protein expression of E-cadherin in a dose-dependent manner, and downregulate the expressions of N-cadherin and Vimentin.
Dose-dependently down-regulates the protein expression of HMGB1.
Inhibited the activation of the NF-κB pathway resulting in a decrease in the levels of phosphorylated-p65 and phosphorylated-IκBα.
Significantly upregulated the expression of miR-410-3p in osteosarcoma cells.

Apoptosis Analysis

Cell Line: PC12 cells
Concentration: 10 μM
Incubation Time: pre-treated for 3 h, and then add Aβ1-42 for co-culture for 24 h
Result: Significantly reduced the apoptosis rate caused by Aβ1-42.
Reduced the expression of pro-apoptotic proteins Bax and Cleaved Caspase-3, and increased the expression of anti-apoptotic protein Bcl-2.
体内研究
(In Vivo)

(+)-Magnoflorine (1-10 mg/kg,腹腔注射,每日一次,持续一个月) 可显著改善阿尔茨海默病 (AD) 模型小鼠的认知功能障碍。
(+)-Magnoflorine (10-20 mg/kg,灌胃,每日一次,持续 15 天) 对大鼠脑缺血再灌注损伤具有保护作用。
(+)-Magnoflorine (10 mg/kg,灌胃,每日一次,持续 10 天) 可缓解 DDS (MS-A45736) 诱导的小鼠结肠炎及其伴随的焦虑样行为。
(+)-Magnoflorine (5-10 mg/kg,灌胃,每日一次,持续 12 周) 在高脂肪高果糖饮食诱发的慢性肾病小鼠模型中表现出肾脏保护作用。

Animal Model: AD model established in APP/PS1 (APPswe/PSEN1dE9) double-transgenic mice (8 months, 30-32 g, female)
Dosage: 1 and 10 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for a month
Result: Improved the learning and memory abilities of mice.
Reduced the core pathological changes in the brain, including Aβ deposition, excessive phosphorylation of Tau protein, neuroinflammation and neuronal loss.
Animal Model: Middle cerebral artery occlusion (MCAO) models model established in male Sprague-Dawley rats (weighing 220 g)
Dosage: 10 and 20 mg/kg
Administration: Intragastric administration (i.g.), once daily for 15 days
Result: Significantly reduced the neurological deficit score, indicating that it improved motor, balance and sensory functions.
Significantly reduced the volume of cerebral infarction and decreased the brain water content.
Reduced the number of damaged neurons shown by Nissl staining and increased the density of NeuN-positive neurons.
Reduced the upregulation of LC3 fluorescence intensity and the LC3-II/LC3-I ratio caused by cerebral ischemia, and increased the expression of p62, Sirt1 and p-AMPK proteins.
Animal Model: Colitis models model established in female C57BL/6 J mice (6-8 weeks old)
Dosage: 10 mg/kg
Administration: Intragastric administration (i.g.), once daily for 10 days
Result: Reduced the disease activity index, the length of the colon, the tissue pathological damage, and decreased the mRNA levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in the colon tissue.
Significantly improved the anxiety-like behaviors induced by DSS.
Inhibited the activation of microglia (IBA1+) in the hippocampus caused by DSS.
Reduced the mRNA levels of TNF-α, IL-1β, and IL-6 in the hippocampal tissue, and upregulated the expression of tight junction proteins ZO-1 and PV1 in the choroid plexus and blood-brain barrier.
Promoted the production of secondary bile acid HDCA by the microbiota.
Animal Model: Chronic kidney disease model established in male C57BL/6 J mice (20 g)
Dosage: 5 and 10 mg/kg
Administration: Intragastric administration (i.g.), once daily for 12 weeks
Result: Significantly reduced the levels of serum creatinine, urea nitrogen, uric acid and elevated urine protein.
Reduced the fatty degeneration of renal tubules, lipid deposition and tubular dilation.
Reduced the collagen deposition in the kidneys, and downregulated the mRNA and protein expressions of fibrosis-related markers (TGF-β, α-SMA, COL-I, COL-III).
Reduced the levels of reactive oxygen species (ROS) and malondialdehyde (MDA) in the kidneys, and increased the activity of total superoxide dismutase (T-SOD).
Inhibited the activation of the NLRP3 inflammasome (reduced the expression of NLRP3, ASC, Cleaved Caspase-1, GSDMD-N and IL-1β).

化学信息

分子量 342.41
分子式 C20H24NO4+
CAS No. 2141-09-5
别名 Magnoflorine; α-Magnoflorine; Thalictrine

储存&溶解度

溶解度信息
DMSO: 34.24 mg/mL (100 mM), Sonication is recommended.
Chloroform, Dichloromethane, Ethyl Acetate, Acetone, etc.: Soluble
体内实验配方
10% DMSO+90% Saline: 3.57 mg/mL (10.43 mM), Solution.
10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline: 10 mg/mL (29.2 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

(+)-木兰花碱 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础